Leukocyte and neutrophil mean cell counts remained within normal range between screening, baseline and throughout the pivotal Phase 3 (leukocytes: normal range 4.010.0 109/L mean count at Day 182: 6.6 109/L with garadacimab [n = 39], 6.2 109/L with placebo [n = 24], neutrophils: normal range 2.07.0 109/L, mean count at Day 182: 4.0 109/L with garadacimab, 3.9 109/L with placebo) and OLE studies (At Month 12 [n = 140]: leukocytes: 6.4 109/L
Critics argue that the definition of UPF needs refinement, and more clinical studies are required
Merchandising clusters these products between supplements and better-for-you snacks, guided by cues like helps you feel satisfied on fewer calories. Consumers start comparing satiety per serving, not just calories per serving, which raises the bar for proof and consistency
[DOI] [Google Scholar] Khanna A
Currently, there is limited evidence on the safety and efficacy of intermittent dosing strategies, and the consensus among obesity specialists is that this approach is not generally advised except in specific clinical scenarios under close supervision
Both remain on the FDAs restricted compounding list as of May 2026
